



Live Virtual Symposium

JANSSEN SATELLITE SYMPOSIUM
ESH 2ND TRANSLATIONAL RESEARCH E-CONFERENCE:
CHRONIC LYMPHOCYTIC LEUKAEMIA

TRANSLATING SCIENTIFIC ADVANCES INTO CLINICAL SUCCESS IN CLL

SCIENTIFIC COMMITTEE

Kostas Stamatopoulos, Greece
Paolo Ghia, Italy

FACULTY

Richard Rosenquist, Sweden
Carol Moreno, Spain

WELCOME

It is our pleasure to welcome you to this satellite symposium entitled **“Translating scientific advances into clinical success in CLL”**.

We know that in recent years there have been significant advances both in our understanding of the biology of CLL and in the therapeutic options available to manage our patients. In this symposium, we will discuss how this improved understanding of disease biology is leading to improved clinical outcomes and how we can ensure maximum outcomes for our patients by harnessing the advances in scientific understanding.

We encourage you to submit your questions during the symposium which we will address during the live panel discussion.

On behalf of the faculty, thank you for reserving time for this educational symposium.

Yours sincerely

Scientific committee: **Kostas Stamatopoulos** and **Paolo Ghia**

LIVE
VIRTUAL
BROADCAST

FRIDAY 18 MARCH 2022
13:00-14:00 CET

Program

Duration	Topic	Speaker/s
5	Introduction	K Stamatopoulos
10	Biomarkers in CLL: what do we need today?	R Rosenquist
10	Personalizing patient management: why and how?	C Moreno
30	Panel discussion with Q&A	All faculty, moderated by P Ghia
5	Summary and close	K Stamatopoulos

LEARNING OBJECTIVES

After attending this symposium delegates should be able to:

- Explain how increased knowledge about CLL biology is leading to improved clinical management of patients



MEET OUR FACULTY



SCIENTIFIC COMMITTEE

KOSTAS STAMATOPOULOS

Kostas Stamatopoulos is the Director of the Institute of Applied Biosciences at the Centre for Research and Technology Hellas (CERTH) in Thessaloniki, Greece. He also holds the positions of Visiting Professor in Lymphoid Tumor Biology at Uppsala University in Uppsala, Sweden; and Research Collaborator in the Hematology Department and HCT Unit, George Papanikolaou Hospital in Thessaloniki, Greece. Dr Stamatopoulos has been involved in CLL and lymphoma research since 1994 and has published extensively about the immunobiology of lymphoid malignancies. He is a board member of the European Research Initiative on CLL (ERIC); a founding member of the IMGT CLL-DB initiative and the IgCLL group, both operating under the auspices of ERIC; a board member of the Splenic Lymphoma Group; and a co-author of the *European Hematology Association Roadmap for European Hematology Research: A Consensus Document*. His current research interests include immunogenetics of human lymphoid malignancies, cell signalling, genetic diagnostics, precision medicine in cancer, and patient empowerment in care.

**Don't worry if
you missed our
symposium, you can
view it on-demand
through ESH**

MEET OUR FACULTY



SCIENTIFIC COMMITTEE PAOLO GHIA

Paolo Ghia is Professor of Medical Oncology at the Università Vita-Salute San Raffaele; and Deputy Chairman of the Division of Experimental Oncology, at the Ospedale San Raffaele. He is Head of the Laboratory of B-Cell Neoplasia and Director of the Strategic Research Program on CLL, where he is national coordinator or principal investigator in clinical trials on CLL and related disorders, including phase 1 studies. Professor Ghia is President of the European Research Initiative on CLL (ERIC), collaborating on the guidelines for the detection of Minimal Residual Disease (MRD) for the analysis of the mutational status of the immunoglobulin (IGHV) genes and of the TP53 gene aberrations. He is also a member of the International Workshop on CLL (iwCLL) and of the WHO Clinical Advisory Committee for Lymphocytic and Histiocytic Malignancies for CLL, monoclonal B-cell lymphocytosis, and prolymphocytic leukemia. He coauthors the EHA-ESMO guidelines for CLL treatment. He is currently Associate Editor for CLL at *Hemasphere*, the official journal of the European Hematology Association (EHA).

**Don't worry if
you missed our
symposium, you can
view it on-demand
through ESH**

MEET OUR FACULTY



FACULTY

RICHARD ROSENQUIST

Richard Rosenquist Brandell is Professor of Clinical Genetics at the Department of Molecular Medicine and Surgery, Karolinska Institutet, and Senior Physician in Clinical Genetics at Karolinska University Hospital, Sweden. He is also Director of Genomic Medicine Sweden, a national infrastructure for implementing precision medicine. Professor Rosenquist has made outstanding contributions to the understanding of the mechanisms behind the development of CLL and other lymphomas. His studies have identified novel prognostic and predictive markers, defined new clinically relevant subgroups, and provided significantly improved risk stratification at the individual patient level.

**Don't worry if
you missed our
symposium, you can
view it on-demand
through ESH**

MEET OUR FACULTY



FACULTY CAROL MORENO

Carol Moreno is Associate Professor of Medicine at the Autonomous University of Barcelona and Senior Consultant at the Department of Hematology at the Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Spain, where she combines clinical work in the Department of Hematology with research activity in the Oncology/Hematology and Transplantation Group of the Biomedical Research Institute of Sant Pau (IIB-Sant Pau). She leads the CLL program at the Hospital Santa Creu I Sant Pau and is the principal investigator of numerous clinical trials. Professor Moreno is a board member of the European Hematology Association and the European Research Initiative on CLL, and is involved in numerous clinical and translational projects. She is also a Secretary of the Spanish Group on Hematological Malignancies in the Elderly, a member of the Scientific Committee of the José Carreras Leukemia Research Institute, and coordinator of the research committee at the Spanish Society of Hematology. Furthermore, she has recently been appointed as an academic member in the Royal European Academy of Doctors (RAED). She has published more than 70 papers in peer-reviewed journals.

**Don't worry if
you missed our
symposium, you can
view it on-demand
through ESH**

Organized and supported by Janssen Pharmaceutical
Companies of Johnson & Johnson in EMEA

Janssen Pharmaceutica NV
Turnhoutseweg 30, 2340 Beerse, Belgium

EM-89951

Date of preparation: February 2022

Copyright © 2022 Janssen Pharmaceutica NV